Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02072356 | Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Early Phase 1 | 290 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT04974281 | PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC | unknown | Early Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03982407 | 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma | completed | Early Phase 1 | 5 | Ajit H. Goenka, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05154812 | Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio | unknown | Early Phase 1 | 108 | Beijing Ditan HospitalOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05152498 | Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC) | unknown | Early Phase 1 | 142 | Beijing Ditan HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05088733 | Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA) | unknown | Early Phase 1 | 120 | Beijing Ditan HospitalOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05105815 | Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma | unknown | Early Phase 1 | 23 | Huashan HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04264962 | Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter(YYFZJDTRHCLT3D) | completed | Early Phase 1 | 300 | Beijing Ditan HospitalOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT05007587 | Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC | unknown | Early Phase 1 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT03291379 | Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies(VEROnA) | completed | Early Phase 1 | 8 | Boston Scientific CorporationINDUSTRY | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04951141 | Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2021 | clinicaltrials |
| NCT02550327 | Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer | completed | Early Phase 1 | 20 | Baylor Research InstituteOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03851471 | Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma | completed | Early Phase 1 | 10 | Zhong WangOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03888859 | ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma | completed | Early Phase 1 | 12 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT04518774 | Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial | unknown | Early Phase 1 | 8 | Beijing 302 HospitalOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT02927626 | Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma(YYFZTIHBVHCC) | completed | Early Phase 1 | 132 | Beijing Ditan HospitalOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | terminated | Early Phase 1 | 2 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02153450 | Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer | completed | Early Phase 1 | 8 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT03965546 | ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer | unknown | Early Phase 1 | 27 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04048317 | Effectiveness of Drug Eluting TACE in Primary HCC | unknown | Early Phase 1 | 75 | Assiut UniversityOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT02847000 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | completed | Early Phase 1 | 13 | Yogen SaunthararajahOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT03672305 | Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC | unknown | Early Phase 1 | 50 | The Second Hospital of Nanjing Medical UniversityOTHER | 0 | Sep 18, 2018 | clinicaltrials |
| NCT01962649 | A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green | completed | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01247298 | A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma(RAD 0902) | completed | Early Phase 1 | 17 | University of Alabama at BirminghamOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT02929797 | Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer(AKT) | unknown | Early Phase 1 | 72 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT02287168 | Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients | completed | Early Phase 1 | 34 | Bezmialem Vakif UniversityOTHER | 1 | Mar 29, 2016 | clinicaltrials |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | University of VirginiaOTHER | 1 | Mar 18, 2016 | clinicaltrials |
| NCT02707315 | A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer | unknown | Early Phase 1 | 15 | The Cooper Health SystemOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01968629 | 24hr Imaging Of HCC After EOVIST | withdrawn | Early Phase 1 | 0 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2015 | clinicaltrials |
| NCT02325999 | Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer | unknown | Early Phase 1 | 200 | Beijing Friendship HospitalOTHER | 1 | Dec 25, 2014 | clinicaltrials |
| NCT00835679 | Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery | terminated | Early Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01403103 | Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jan 17, 2014 | clinicaltrials |
| NCT01337492 | Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) | terminated | Early Phase 1 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 21, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Sep 30, 2022source: clinicaltrials